A Phase I/II Clinical Trial of Fludarabine, Bendamustine, and Rituximab (FBR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL).

Trial Profile

A Phase I/II Clinical Trial of Fludarabine, Bendamustine, and Rituximab (FBR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Bendamustine (Primary) ; Fludarabine (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 10 Aug 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017, as reported by ClinicalTrials.gov.
    • 08 Aug 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top